“…Regarding the function of miR-107 in cancer, reduced miR-107 expression has been reported in various types of cancer 69–78 , and several recent studies have identified the tumor suppressor functions of miR-107. One crucial function of miR-107 that has been identified is the inhibition of oncogenes, such as CDK8 in breast cancer 71 , the ATR/Chk1 pathway in cervical cancer 79 , HIF-1, CCND1, and NFKB1 in colon cancer 80, 81 , CDK in gastric cancer 70 , CDK6, Notch-2, and VEGF in glioma 74, 75, 82, 83 , CDK6 and CDK8 in non-small cell lung cancer 84, 85 , GRN in prostate cancer 78 , eukaryotic translation initiation factor 5 in renal clear cell carcinoma 86 , and CDK6 in PCa 87 . Furthermore, some studies have demonstrated that the tumor suppressor p53 inhibits tumor angiogenesis and cell growth through the transcriptional regulation of miR-107 in several cancer types 74, 80 .…”